Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

JAK2 inhibition mediates clonal selection of RAS pathway mutations in myeloproliferative neoplasms

7 Jul 2025

Abstract excerpt

Abstract JAK (Janus Kinase) inhibitors, such as ruxolitinib, were introduced a decade ago for treatment of myeloproliferative neoplasms (MPN). To evaluate ruxolitinib’s impact on MPN clonal evolution, we interrogate a myelofibrosis patient cohort with longitudinal molecular evaluation and discover that ruxolitinib is associated with clonal outgrowth of RAS pathway mutations. Single-cell DNA sequencing combined...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Eosinophilic Disorders and Syndromes
Share to Myeloproliferative Neoplasms: Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40623967
DOI: 10.1038/s41467-025-60884-1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

JAK2 inhibition mediates clonal selection of RAS pathway mutations in myeloproliferative neoplasmsPMID 40623967Read ↗

Single-cell analysis based dissection of clonality in myelofibrosis.Semantic proximity Read ↗

Efficacy of JAK1/2 inhibition in murine myeloproliferative neoplasms is not mediated by targeting oncogenic signalingSemantic proximity Read ↗

Clonal architecture evolution in Myeloproliferative Neoplasms: from a driver mutation to a complex heterogeneous mutational and phenotypic landscape.Semantic proximity Read ↗

Therapy-Induced Clonal Selection as a Driver of Response to JAK Inhibitors in MyelofibrosisSemantic proximity Read ↗

Clonal heterogeneity as a driver of disease variability in the evolution of myeloproliferative neoplasms.Semantic proximity Read ↗

Single-cell approaches identify the molecular network driving malignant hematopoietic stem cell self-renewalSemantic proximity Read ↗

Effects of the JAK2 mutation on the hematopoietic stem and progenitor compartment in human myeloproliferative neoplasmsSemantic proximity Read ↗

The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms.Semantic proximity Read ↗

The pan-PIM inhibitor INCB053914 displays potent synergy in combination with ruxolitinib in models of MPNSemantic proximity Read ↗

Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.Semantic proximity Read ↗

Clonal independence of JAK2 and CALR or MPL mutations in comutated myeloproliferative neoplasms demonstrated by single cell DNA sequencing.Semantic proximity Read ↗

Effects of JAK1/2 inhibition on bone marrow stromal cells of myeloproliferative neoplasm (MPN) patients and healthy individuals.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.